NEW YORK (Reuters Health) – Ranibizumab injections may be safely used for at least three years in
patients with neovascular age-related macular degeneration (nAMD), according to findings from the SECURE
study.
Author: ModernMedecine
Cat antigen desensitization reduces allergic rhinoconjunctivitis symptoms
NEW YORK (Reuters Health) – Desensitization with a Fel d 1-derived peptide antigen (Cat-PAD) reduces
allergic rhinoconjunctivitis symptoms up to a year after the start of dosing.
Dry eye common after eyelid lifts
NEW YORK (Reuters Health) – More than one-quarter of people who’ve had an eyelid lift report symptoms
of dry eye such as excessive watering and irritation, a new study suggests.
FDA approves treatment for cystinosis
The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for
corneal cystine crystal accumulation in patients with cystinosis.
Laser cleared for flap creation
The FDA has cleared the additional indication of corneal flap creation in refractive surgical
procedures for the LenSx Laser (Alcon).
Nasolacrimal duct stent cleared
FCI Ophthalmics has received 510(k) clearance for the Masterka pushed monocanalicular nasolacrimal
intubation stent.
Foldable IOL findings favorable
A Canadian trial including 120 subjects is investigating the safety and efficacy of an acrylic,
foldable, single-piece, angle-supported phakic IOL (AcrySof Cachet, Alcon).
Moderate cumulative dose of IV methylprednisolone best for active Graves’ orbitopathy
NEW YORK (Reuters Health) – An intermediate cumulative dose of IV methylprednisolone may be the best
approach for active Graves’ orbitopathy, a new study from Europe indicates.
Moderate cumulative dose of IV methylprednisolone best for active Graves’ orbitopathy
NEW YORK (Reuters Health) – An intermediate cumulative dose of IV methylprednisolone may be the best
approach for active Graves’ orbitopathy, a new study from Europe indicates.
Patient selection key to IOL choice
Proper patient selection is the key to choosing successfully between multifocal and aspheric
accommodating IOLs. The advantages and disadvantages of both must be carefully considered.
FDA panel recommends approval of retinal prosthesis
An FDA panel has recommended approval of the Argus II Retinal Prosthesis System (Second Sight Medical
Products Inc.) for treatment of patients with retinitis pigmentosa.
New treatment for dry AMD
The first patient to receive purified human neural stem cells (HuCNS-SC, StemCells, Inc.) as a
treatment for AMD has now undergone transplantation.
Steroid gel gets FDA approval
A 0.5% gel drop formulation of loteprednol etabonate (Lotemax, Bausch + Lomb) is now available for
postoperative inflammation and pain.
Pure cataract meeting lets presenters share experiences uncensored
A video description of Cataract Surgery: Telling It Like It Is!, cataract meeting organized by Robert
H. Osher, MD.
Monthly ranibizumab injections may be needed to control diabetic macular edema
NEW YORK (Reuters Health) – Three-year outcomes from the READ-2 study show that ranibizumab
(Lucentis;
Retinal implant helps blind patients detect motion
NEW YORK (Reuters Health) – Blind patients fitted with a retinal prosthesis system are able to
accurately detect motion, according to a new report in the Archives of Ophthalmology.
Ranibizumab may help drivers with macular degeneration
NEW YORK (Reuters Health) – In patients with age-related macular degeneration (AMD), ranibizumab
(Lucentis, Genentech) seems to improve self-reported driving ability more than sham treatment or photodynamic
therapy, according to researchers.
Rho kinase inhibitor starts phase IIa study
A phase IIa proof of concept study of a novel rho kinase (ROCK) inhibitor, AMA0076 (Amakem NV), is now
underway in patients with glaucoma and ocular hypertension.
Rho-kinase inhibitor in phase IIa study
A phase IIa proof of concept study of a novel rho-kinase (ROCK) inhibitor (AMA0076, Amakem NV) is now
underway in patients with glaucoma and ocular hypertension.
IIH mechanisms clarified
To clarify whether total intracranial CSF volume increases in IIH, researchers prospectively studied
MRI-derived measures of total cranial, ventricular, and extraventricular CSF volumes in patients with IIH and
controls. Results showed that the…